PLAZMOCITNA LEUKEMIJA

Predrag Đurđević; Danijela Jovanović

doi:10.5937/smclk6-52536

Predrag Đurđević Klinika za hematologiju, Univerzitetski klinički centar Kragujevac; Fakultet medicinskih nauka, Univerzitet u Kragujevcu, Kragujevac, Srbija
Danijela Jovanović Klinika za hematologiju, Univerzitetski klinički centar Kragujevac; Fakultet medicinskih nauka, Univerzitet u Kragujevcu, Kragujevac, Srbija

DOI: https://doi.org/10.5937/smclk6-52536

Ključne reči: plazmocitna leukemija, citogenetske abnormalnosti, imunomodulatorni lekovi

Sažetak

Plazmocitna leukemija je veoma retka i agresivna forma plazmocitne diskrazije koju odlikuje loša prognoza, kratko preživljavanje i loš odgovor na primenjenu terapiju. Kliničke manifestacije su različite, ali se najčešće sreće ekstramedularna forma bolesti, hiperkalcemija, anemija, trombocitopenija, oštećenje bubrežne funkcije i povećanje koncentracije laktat dehidrogenaze. Postoje brojne citogenetske abnormalnosti koje dovode do veće proliferacije, inhibicije apoptoze, promene u ekspresiji adhezivnih molekula i hemokinskih receptora. I pored uvođenja novih terapijskih modaliteta zasnovanih na primeni bortezomiba i imunomodulatornih lekova, kao i primeni biološke terapije, terapijski ishod je još uvek nezadovoljavajući.

Reference

Jelinek T, Kryukov F, Rihova L, Hajek R. Plasma cell leukemia: from biology to treatment. Eur J Haematol. 2015 Jul;95(1):16-26. doi: 10.1111/ejh.12533.

Jung SH, Lee JJ. Update on primary plasma cell leukemia. Blood Res. 2022 Apr 30;57(S1):62-6. doi: 10.5045/br.2022.2022033.

Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, et al.; International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336.

Gundesen MT, Lund T, Moeller HEH, Abildgaard N. Plasma cell leukemia: definition, presentation, and treatment. Curr Oncol Rep. 2019 Jan 28;21(1):8. doi: 10.1007/s11912-019-0754-x.

Rojas EA, Gutiérrez NC. Genomics of plasma cell leukemia. Cancers (Basel). 2022 Mar 21;14(6):1594. doi: 10.3390/cancers14061594.

Swami VK, Dwyer-Joyce LEA. Clinical pathology rounds: diagnosing plasma cell leukemia. Lab Med. 2000 Jun 1;31(6):312-5. doi: 10.1309/K6WB-G6GE-82A9-KK4P.

Gowin K, Skerget S, Keats JJ, Mikhael J, Cowan AJ. Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment. Leuk Res. 2021 Dec;111:106687. doi: 10.1016/j.leukres.2021.106687.

van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood. 2012 Sep 20;120(12):2376-89. doi: 10.1182/blood-2012-05-408682.

Tuazon SA, Holmberg LA, Nadeem O, Richardson PG. A clinical perspective on plasma cell leukemia: current status and future directions. Blood Cancer J. 2021 Feb 4;11:23. doi: 10.1038/s41408-021-00414-6.

Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008 May;22(5):1044-52. doi: 10.1038/leu.2008.4.

Singh ZN, Owens RB, Nair B, Shaughnessy JJr, Barlogie B. Loss of chemokine receptor expression and tetrasparins is correlated with extramedullary disease in multiple myeloma. Blood. 2010 Nov 19;116(21):2983. doi: 10.1182/blood.V116.21.2983.2983.

Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, et al.; for GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party: coordinator Sergio Amadori). Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol. 2011 Jul;22(7):1628-35. doi: 10.1093/annonc/mdq646.

Yu T, Xu Y, An G, Tai YT, Ho M, Li Z, et al. Primary plasma cell leukemia: real-world retrospective study of 46 patients from a single-center study in China. Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e652-9. doi: 10.1016/j.clml.2020.05.014.

Schinke C, Boyle EM, Ashby C, Wang Y, Lyzoguboiv V, Wardell C, et al. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer J. 2020 Jun 19;10(6):70. doi: 10.1038/s41408-020-0336-z.

Čolović M, Janković G, Suvajdžić N, Milić N, Đorđević V, Janković S. Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol. 2008;25(2):154-60. doi: 10.1007/s12032-007-9011-5.

Musto P. Progress in the treatment of primary plasma cell leukemia. J Clin Oncol. 2016 Jun 20;34(18):2082-4. doi: 10.1200/JCO.2016.66.6115.

Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, et al. Real-world data on prognosis and outcome of prim,ary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6.

van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KL, Broijl A, et al. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. Lancet Oncol. 2023 Oct;24(10):1119-33. doi: 10.1016/S1470-2045(23)00405-9.

Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D, et al. Primary plasma cell leukemia and autologous stem cell transplantation Haematologica. 2010 May;95(5):804-9. doi: 10.3324/haematol.2009.013334.

Jung SH, Lee JJ, Kim K, Suh C, Yoon DH, Min CK, et al.; Korean Multiple Myeloma Working Party. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget. 2017 Jun 16;8(45):79517-26. doi: 10.18632/oncotarget.18535.

Mahindra A, Kalaycio ME, Vala-Ojeda J, Vesole DH, Zhang MJ, Li P, et al. Haematoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012 May;26(5):1091-7. doi: 10.1038/leu.2011.312.